Project Grant R01AI193619
Award Date 8/14/26
Completion Date 7/31/31
Dollars Obligated $757K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $229,714 on April 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate RNA ribosylation's role in viral RNA biology and innate immunity. The research examines how post-transcriptional mRNA modifications affect viral replication and host innate immune sensing, with focus on ADP-ribosylation (ADPR)—an important post-translational...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $2.94 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 18, 2025, with a completion date of July 31, 2029. This award supports the development and clinical advancement of ACE2 immunodecoys as long-lasting immunoprophylaxis against sarbecoviruses and merbecoviruses that target...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $251,324 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered organ transplants resistant to antibody-mediated rejection through synthetic biology platforms. The research focuses on designing signal-inducible, drug-controllable endopeptidases for localized antibody degradation within transplanted tissue. The award funds...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $753,256 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify molecular biomarkers and develop improved animal models for Chlamydia trachomatis vaccine development. The project will profile cervical transcriptional immune responses to chlamydial infection and challenge across three mouse groups—naive, infection-immune (previously...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $553,779 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate translation regulation mechanisms during human cytomegalovirus infection. The research examines how HCMV manipulates host cell protein synthesis machinery to support viral replication. Unlike many viruses that inhibit host translation, HCMV infection increases overall...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $756,936 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop broadly protective medical countermeasures against merbecovirus and sarbecovirus through nanoparticle immunogen design. The research aims to elicit broadly neutralizing antibodies targeting conserved viral epitopes on the receptor binding domain and stem helix of coronavirus spike proteins. Preliminary...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $233,250 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize T cell profiles induced by monovalent and bivalent HIV vaccination in people with HIV on antiretroviral therapy. The research examines whether increased cross-recognition following bivalent HIV vaccination improves T cell-mediated recognition and inhibition of...
- The National Institute of Allergy and Infectious Diseases awarded $194,375 to the University of North Carolina at Chapel Hill on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bifunctional molecules targeting HIV latency reversal through BRD4 recruitment to the viral promoter. The research addresses the heterogeneity of the viral reservoir and multiple mechanisms maintaining HIV latency, which single latency reversal agents cannot overcome. The...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 8, 2025, with a completion date of August 31, 2027. This research initiative advances the development of laboratory tools and methodologies to characterize the natural humoral immune response to sapovirus (SAV) following...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into phage-mediated reprogramming of the gut microbiome to suppress chronic inflammation in inflammatory bowel disease. The funded research, R21AI197116, engineers self-complementary non-replicative phage vectors to deliver therapeutic genetic modifications to existing...